A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1: Number of Participants From ≥1 Month to <12 Years Who Experience a Dose-limiting Toxicity (DLT)

  Measured over: Cycle 1 (up to approximately 21 days); each cycle is 21 days

• Part 1: Number of Participants From ≥1 Month to <12 Years Who Experience One or More Adverse Events (AEs)

  Measured over: Up to approximately 5 years

• Part 1: Number of Participants From ≥1 Month to <12 Years Who Discontinue Study Intervention Due to an AE

  Measured over: Up to approximately 5 years

• Part 1: Number of Participants From ≥1 Month to <12 Years Who Receive Dose Modifications Due to AEs

  Measured over: Up to approximately 5 years

• Part 1 and Part 2: Objective Response Rate (ORR) for Participants with neuroblastoma (NBL), rhabdomyosarcoma (RMS), and Wilms tumor (WT)

  Measured over: Up to approximately 5 years

• Part 1 and Part 2: Disease Control Success at 4 Months (DCS-4) for Participants with osteosarcoma (OST)

  Measured over: Up to 4 Months

Changes Tremor has spotted